Increased insulin clearance in peroxisome proliferator-activated receptor γ2 Pro12Ala

被引:26
|
作者
Tschritter, O [1 ]
Fritsche, A [1 ]
Stefan, N [1 ]
Haap, M [1 ]
Thamer, C [1 ]
Bachmann, O [1 ]
Dahl, D [1 ]
Maerker, E [1 ]
Teigeler, A [1 ]
Machicao, F [1 ]
Häring, H [1 ]
Stumvoll, M [1 ]
机构
[1] Univ Tubingen, Med Klin, Abt Endokrinol Stoffwechsel & Pathochem, D-72076 Tubingen, Germany
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2003年 / 52卷 / 06期
关键词
D O I
10.1016/S0026-0495(03)00071-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPARgamma2) is associated with reduced risk for type 2 diabetes. Although increased insulin sensitivity of glucose disposal and lipolysis has been reported, the exact mechanism by which the risk reduction is conferred is not clear. Because the conclusion of greater insulin sensitivity hinged upon lower insulin levels in some studies, it is possible that more efficient insulin clearance is involved. We therefore estimated insulin clearance during a euglycemic hyperinsulinemic clamp (insulin infusion rate divided by steady-state insulin concentration, 229 normal glucose tolerant [NGT] subjects), an oral glucose tolerance test (OGTT) (mean C-peptide divided by mean insulin concentrations, 406 NGT, 54 impaired glucose tolerant or mildly diabetic subjects), and a hyperglycemic clamp (120 minutes, 10 mmol/L, C-peptide divided by insulin in the steady-state, 56 NGT subjects). In the carriers of the Ala allele (prevalence similar to24%), insulin clearance in all 3 protocols was significantly greater (similar to 10%), than in controls. While the results from the euglycemic clamp reflect both hepatic and peripheral insulin clearance; those from the OGTT and the hyperglycemic clamp reflect mainly hepatic insulin extraction. Free fatty acids (FFA) during the steady state of the euglycemic hyperinsulinemic clamp were significantly lower in carriers of the Ala allele (26 +/- 5 mumol/L) than in controls (46 +/- 3 mumol/L, P = .02). In conclusion, the Pro12Ala polymorphism is associated with increased insulin clearance. This could be the result of reduced FFA delivery, which has been shown to improve hepatic insulin removal and sensitivity. Because PPARgamma2 is mainly expressed in adipose tissue, one of the main regulatory effects of the polymorphism may well be the more efficient suppression of (possibly intra-abdominal) lipolysis. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:778 / 783
页数:6
相关论文
共 50 条
  • [21] Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population
    Sánchez, JLG
    Ríos, MS
    Pérez, CF
    Laakso, M
    Larrad, MTM
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 147 (04) : 495 - 501
  • [22] Correlation of Peroxisome Proliferator-Activated Receptor (PPAR-γ) mRNA Expression with Pro12Ala Polymorphism in Obesity
    Berhouma, Rym
    Kouidhi, Soumaya
    Ammar, Myriam
    Abid, Hafawa
    Ennafaa, Hajer
    Benammar-Elgaaied, Amel
    BIOCHEMICAL GENETICS, 2013, 51 (3-4) : 256 - 263
  • [23] Peroxisome proliferator-activated receptor-γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk
    Wang, Wei
    Shao, Yan
    Tang, Shenhua
    Cheng, Xianyong
    Lian, Haifeng
    Qin, Chengyong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (03): : 4066 - 4072
  • [24] Pro12Ala mutation in the peroxisome proliferator-activated receptor γ2 (PPARγ2) and severe obesity: a case–control study
    O Vaccaro
    FP Mancini
    G Ruffa
    L Sabatino
    V Colantuoni
    G Riccardi
    International Journal of Obesity, 2000, 24 : 1195 - 1199
  • [25] Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes
    Kang, ES
    Park, SY
    Kim, HJ
    Kim, CS
    Ahn, CW
    Cha, BS
    Lim, SK
    Nam, CM
    Lee, HC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) : 202 - 208
  • [26] Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population
    Namvaran, Fatemeh
    Rahimi-Moghaddam, Parvaneh
    Azarpira, Negar
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2011, 16 (03): : 291 - 296
  • [27] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ Pro12Ala POLYMORPHISM AND RISK OF OSTEOPENIA IN β-THALASSEMIA MAJOR PATIENTS
    Sahmani, Mehdi
    Gholami, Abdollah
    Azarkeivan, Azita
    Darabi, Masoud
    Ahmadi, Mohammad Hossein
    Sabet, Majid Sirati
    Najafipour, Reza
    HEMOGLOBIN, 2013, 37 (06) : 564 - 573
  • [28] Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome
    Yilmaz, Murat
    Erguen, Mehmet Ali
    Karakoc, Ayhan
    Yurtcu, Erkan
    Çakir, Nuri
    Arslan, Metin
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (06) : 336 - 342
  • [29] Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus
    Ringel, J
    Engeli, S
    Distler, A
    Sharma, AM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 254 (02) : 450 - 453
  • [30] Correlation of Peroxisome Proliferator-Activated Receptor (PPAR-γ) mRNA Expression with Pro12Ala Polymorphism in Obesity
    Rym Berhouma
    Soumaya Kouidhi
    Myriam Ammar
    Hafawa Abid
    Hajer Ennafaa
    Amel Benammar-Elgaaied
    Biochemical Genetics, 2013, 51 : 256 - 263